Singapur - angličtina - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - aflibercept - injection, solution - 2.0mg/50mcl - aflibercept 2.0mg/50mcl

Singapur - angličtina - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - aflibercept - injection, solution - 2.0mg/50mcl - aflibercept 2.0mg/50mcl

Európska únia - angličtina - EMA (European Medicines Agency)

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - eylea is indicated for adults for the treatment of:neovascular (wet) age-related macular degeneration (amd);visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo);visual impairment due to diabetic macular oedema (dme);visual impairment due to myopic choroidal neovascularisation (myopic cnv).

Kanada - angličtina - Health Canada

bayer inc - aflibercept - solution - 2mg - aflibercept 2mg - eent drugs, miscellaneous

Arménsko - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

bayer pharma ag - aflibercept - solution for injection - 40mg/ml

Izrael - angličtina - Ministry of Health

bayer israel ltd - aflibercept - solution for intravitreal injection - aflibercept 40 mg/ml - aflibercept - eylea is indicated for adults for the treatment of • neovascular (wet) age-related macular degeneration (amd)• visual impairment due to macular oedema secondary to retinal vein occlusion (branch crvo or central rvo)• visual impairment due to diabetic macular oedema (dme)• visual impairment due to myopic choroidal neovascularisation (myopic cnv).

Arménsko - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

bayer ag - aflibercept - solution for injection - 40mg/ml

Kanada - angličtina - Health Canada

bayer inc - aflibercept - solution - 2mg - aflibercept 2mg - eent drugs, miscellaneous

Európska únia - angličtina - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - ophthalmologicals - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5.1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5.1),visual impairment due to diabetic macular oedema (dme) (see section 5.1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.1).

Kanada - angličtina - Health Canada

bayer inc - aflibercept - solution - 8mg - aflibercept 8mg